Wolverine Trading’s PDL BioPharma, Inc. PDLI Stock Holding History

Wolverine Trading’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,100	Closed	-$33K	–	5726
2019 Q4	$33K	Buy	+10,100	New	+$29.3K	﹤0.01%	4524
2018 Q3	–	Sell	-15,100	Closed	-$44K	–	6535
2018 Q2	$44K	Hold	15,100	–	–	﹤0.01%	4927
2018 Q1	$44K	Sell	15,100 -10,500	-41%	-$28.7K	﹤0.01%	4927
2017 Q4	$70K	Sell	25,600 -3,100	-11%	-$9.52K	﹤0.01%	4547
2017 Q3	$97K	Sell	28,700 -4,000	-12%	-$11.1K	﹤0.01%	4077
2017 Q2	$84K	Buy	+32,700	New	+$75.2K	﹤0.01%	3945
2017 Q1	–	Sell	-28,700	Closed	-$61K	–	5592
2016 Q4	$61K	Sell	28,700 -9,300	-24%	-$25.9K	﹤0.01%	4180
2016 Q3	$123K	Buy	38,000 +23,400	+160%	+$74.3K	﹤0.01%	4099
2016 Q2	$46K	Buy	+14,600	New	+$48.7K	﹤0.01%	3826

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wolverine Trading's PDLI Position: Q3 2018 in Review

Wolverine Trading sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 17,903 shares — an estimated $53K sold.

Wolverine Trading first reported a position in PDLI in Q3 2016 and held it in 5 quarters. The position peaked at $53K in Q2 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Wolverine Trading reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Wolverine Trading sold 17,903 PDL BioPharma, Inc. shares in Q3 2018, an estimated $53K.
Wolverine Trading first reported a position in PDL BioPharma, Inc. in Q3 2016 and held it in 5 quarters.
Wolverine Trading's PDL BioPharma, Inc. position peaked at $53K in Q2 2018.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Wolverine Trading's 13F filing for Q3 2018, filed 14 Nov 2018.